LOVE Stock Overview
Engages in the indoor cultivation, processing, and sale of cannabis and cannabis-derivated products in Canada.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Cannara Biotech Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.80 |
| 52 Week High | CA$1.15 |
| 52 Week Low | CA$0.67 |
| Beta | 1.17 |
| 1 Month Change | -1.23% |
| 3 Month Change | -9.09% |
| 1 Year Change | -5.88% |
| 3 Year Change | -36.00% |
| 5 Year Change | -51.52% |
| Change since IPO | -73.77% |
Recent News & Updates
Cannara Biotech Inc.'s (CVE:LOVE) Prospects Need A Boost To Lift Shares
May 09
Here's Why We Think Cannara Biotech (CVE:LOVE) Might Deserve Your Attention Today
Feb 28Investor Optimism Abounds Cannara Biotech Inc. (CVE:LOVE) But Growth Is Lacking
Jan 24Cannara Biotech's (CVE:LOVE) Earnings May Just Be The Starting Point
Dec 18Recent updates
Cannara Biotech Inc.'s (CVE:LOVE) Prospects Need A Boost To Lift Shares
May 09Here's Why We Think Cannara Biotech (CVE:LOVE) Might Deserve Your Attention Today
Feb 28Investor Optimism Abounds Cannara Biotech Inc. (CVE:LOVE) But Growth Is Lacking
Jan 24Cannara Biotech's (CVE:LOVE) Earnings May Just Be The Starting Point
Dec 18Is Cannara Biotech (CVE:LOVE) A Risky Investment?
Jul 29Cannara Biotech Inc.'s (CVE:LOVE) Business Is Yet to Catch Up With Its Share Price
Apr 10Here's Why Cannara Biotech (CVE:LOVE) Has A Meaningful Debt Burden
Jan 26Cannara Biotech's (CVE:LOVE) Earnings Aren't As Good As They Appear
Jan 27Cannara Biotech (CVE:LOVE) Has A Somewhat Strained Balance Sheet
Dec 10Here's Why Cannara Biotech (CSE:LOVE) Can Afford Some Debt
Mar 16Can You Imagine How Cannara Biotech's (CSE:LOVE) Shareholders Feel About The -6.5% Share Price Increase?
Jan 22
Have Insiders Been Buying Cannara Biotech Inc. (CSE:LOVE) Shares?
Dec 18Shareholder Returns
| LOVE | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | 3.9% | -4.5% | 1.2% |
| 1Y | -5.9% | 55.7% | 11.8% |
Return vs Industry: LOVE underperformed the Canadian Pharmaceuticals industry which returned 55.7% over the past year.
Return vs Market: LOVE underperformed the Canadian Market which returned 11.8% over the past year.
Price Volatility
| LOVE volatility | |
|---|---|
| LOVE Average Weekly Movement | 7.4% |
| Pharmaceuticals Industry Average Movement | 14.4% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in CA Market | 17.9% |
| 10% least volatile stocks in CA Market | 2.9% |
Stable Share Price: LOVE's share price has been volatile over the past 3 months.
Volatility Over Time: LOVE's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | n/a | Zohar Krivorot | cannara.ca |
Cannara Biotech Inc., together with its subsidiaries, engages in the indoor cultivation, processing, and sale of cannabis and cannabis-derivated products in Canada. It also offers hemp-based CBD products. The company sells its products through wholesalers and online merchandisers.
Cannara Biotech Inc. Fundamentals Summary
| LOVE fundamental statistics | |
|---|---|
| Market cap | CA$72.92m |
| Earnings (TTM) | CA$6.22m |
| Revenue (TTM) | CA$73.26m |
11.6x
P/E Ratio1.0x
P/S RatioIs LOVE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LOVE income statement (TTM) | |
|---|---|
| Revenue | CA$73.26m |
| Cost of Revenue | CA$42.57m |
| Gross Profit | CA$30.69m |
| Other Expenses | CA$24.47m |
| Earnings | CA$6.22m |
Last Reported Earnings
Feb 29, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.069 |
| Gross Margin | 41.89% |
| Net Profit Margin | 8.49% |
| Debt/Equity Ratio | 61.4% |
How did LOVE perform over the long term?
See historical performance and comparison